Result of Annual General Meet

RNS Number : 3783T

Oxford Biomedica PLC

04 June 2009

 



FOR IMMEDIATE RELEASE	4 JUNE 2009

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING

Oxford, UK - 4 June 2009: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions were duly passed at its Annual General Meeting, held today in London.

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

• Resolution 9: to increase the authorised share capital of the Company to £10,000,000, by the creation of 350,000,000 ordinary shares of 1 penny each;

• Resolution 10: to empower the Directors to allot equity securities, pursuant to section 80 of the Companies Act 1985 (the 'Act'), up to an aggregate nominal amount of £1,798,329, with a further aggregate nominal amount of £1,798,329 authorised in connection with a rights issue, or where applicable, other proportionate offer; 

• Resolution 11: to empower the Directors to allot equity securities for cash, pursuant to section 95 of the Act as if section 89(1) of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares; 

• Resolution 12: in addition to the authority contained in Resolution 11, to empower the Directors to allot equity securities for cash, pursuant to section 95 of the Act as if section 89(1) of the Act did not apply to any such allotment, up to an aggregate nominal amount representing 10 per cent of presently issued shares; 

• Resolution 13: to amend the Company's Articles of Association, and that the Company be permitted to convene general meetings (other than annual general meetings) by not less than 14 days notice; and

• Resolution 14: to amend the Company's Articles of Association to allow the Board of Directors to authorise Directors' conflicts of interest.  

Certified copies of the document setting out the above resolutions passed at the 2009 AGM have been submitted to the UK Listing Authority and will shortly be made available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

The results of the proxy voting in advance of the meeting and the Notice of 2009 AGM (giving the full text of each of the above resolutions) can be viewed by visiting our website at www.oxfordbiomedica.co.uk

-Ends-

For further information, please contact:
Oxford BioMedica plc:  John Dawson, Chief Executive Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court/ Mary-Jane Elliott Buchanan Communications	Tel: [phone]
Scientific/Trade Press Enquiries: Sue Charles/ Holly Griffiths/ John McIntyre College Hill Life Sciences	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline. Partners include sanofi-aventis, Sigma-Aldrich and Wyeth. Technology licensees include Biogen-Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

RAGCKQKBDBKDBAK